Capricor Therapeutics Announced An Update On Its Type-b Clinical Meeting With The FDA On The Design And Execution Of The HOPE-3 Phase 3 Trial With Lead Asset CAP-1002 For Duchenne Muscular Dystrophy
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics has announced an update on its Type-B clinical meeting with the FDA regarding the design and execution of the HOPE-3 Phase 3 trial with lead asset CAP-1002 for Duchenne Muscular Dystrophy.
September 29, 2023 | 11:35 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The update on the Type-B clinical meeting with the FDA regarding the HOPE-3 Phase 3 trial with CAP-1002 could potentially impact Capricor Therapeutics' stock.
The news directly pertains to Capricor Therapeutics and its lead asset CAP-1002. The outcome of the FDA meeting and the subsequent progress of the HOPE-3 Phase 3 trial could significantly impact the company's stock price. However, without specific details on the update, it's difficult to predict the direction of the impact.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100